GGrantIndex
Sort

51,593 grants matching hepatitis

Software for predicting liver injury from biologics drug candidates using data from a human liver microphysiology system

$862,693
Kyunghee Yang · Simulations Plus, Inc. · R44 · FY2022 · TR

A new humanized mouse model to study HBV gene editing

$862,440
Keith R Jerome · Fred Hutchinson Cancer Center · R01 · FY2024 · AI

Biofilm Epidemiology and Mechanisms in Colon Cancer

$862,426
Cynthia L Sears · Johns Hopkins University · R01 · FY2018 · CA

Apolipoprotein C3-loading of apolipoprotein B100 lipoproteins and cardiovascular disease in patients with type 1 diabetes

$862,314
Jay W Heinecke · University Of Washington · R01 · FY2022 · HL

Translational Research and Evolving Alcoholic hepatitis Treatment (TREAT-IU)

$862,255
David W Crabb · Indiana University Indianapolis · U01 · FY2016 · AA

Genetic Determinants of Antidepressant Response

$862,242
Francis J McMahon · National Institute Of Mental Health · ZIA · FY2012 · MH

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

$861,956
Raymond Luke Comenzo · Tufts Medical Center · R01 · FY2024 · CA

P75 Small Molecule Ligands for Alzheimer's Therapy

$861,856
Frank M Longo · Stanford University · U01 · FY2009 · AG

ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM IN AIDS

$861,780
Beth Israel Medical Ctr (New York) · U01 · FY2000 · AI

Natural History of Hepatitis C Infection in HIV Disease

$861,647
Boston University Medical Campus · R01 · FY2005 · DA

Directed Transport Physics and Muli-Scale Therapy of Colon Cancer Liver Metatasis

$861,642
Mauro Ferrari · Methodist Hospital Research Institute · U54 · FY2010 · CA

Improving Hepatitis C Treatment in Injection Drug Users

$861,193
Upstate Medical University · R01 · FY2005 · DA

Cost-Effectiveness of Preventing HIV Complications

$861,119
Kenneth Alan Freedberg · Massachusetts General Hospital · R01 · FY2016 · AI

Task 4: The Interventional Agent Development Services program

$860,629
Jon Carl Mirsalis · Sri International · N01 · FY2014 · AI

MGMT OF INFO RESOURCES ON THERAPEUTIC AGENTS FOR HIV AND OPPORTUNISTIC INFECTIONS

$860,506
Margaret Rush · Gryphon Scientific, Llc · N01 · FY2011 · AI

Amino Acids and Pediatric Hepatic Steatosis

$860,498
Robert R Wolfe · Amino Company Llc, The · R44 · FY2024 · DK

Multidisciplinary Studies of Hematopoietic Malignancies

$860,372
Lindsay Morton · Division Of Cancer Epidemiology And Genetics · ZIA · FY2014 · CA

HEPATITIS C IN NEW IDUS: IMPLICATIONS FOR HIV PREVENTION

$860,023
New York Academy Of Medicine · R01 · FY2002 · DA

Studies of Atomic Bomb Survivors

$860,011
Kiyohiko Mabuchi · Division Of Cancer Epidemiology And Genetics · ZIA · FY2012 · CA

The role of cancer stem cells in liver cancer heterogeneity and subtypes

$859,473
Xin Wei Wang · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

HIV and musculoskeletal frailty: implications for care, policy and research

$859,206
Elena Losina · Brigham And Women'S Hospital · R01 · FY2023 · NR

Cost-Effectiveness of Preventing HIV Complications

$858,653
Kenneth Alan Freedberg · Massachusetts General Hospital · R01 · FY2017 · AI

A therapeutic vaccine for chronic hepatitis B

$858,609
David R. Milich · Vlp Biotech, Inc. · R44 · FY2020 · AI

Elucidating the Molecular Mechanisms that Mediate DKD Progression in Patients Living with HIV

$858,575
John C He · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · DK

Center for the Study of Innate Immunity to HCV Infection

$858,518
Michael J Gale · University Of Washington · U19 · FY2012 · AI